A Phase 3 clinical study for patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

Updated on 25 March 2021


A Phase 3 clinical study for patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).


The overall objective of this study is to assess the efficacy and safety of treatment with PT003 (GFF MDI), PT005 (FF MDI), PT001 (GP MDI), and open-label tiotropium bromide inhalation powder compared with each other and Placebo MDI over 24 weeks in subjects with moderate to very severe COPD.

Clinical Study IdentifierTX137894
Last Modified on25 March 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 40 yrs and 80 yrs?
Gender: Male or Female
Male or female subjects at least 40 years of age and no older than 80 at Visit 1
Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)
Current or former smokers with a history of at least 10 pack-years of cigarette smoking
Average f the -60 and the -30 min pre-dose FEV1 assessments must be < 80% predicted normal value calculated using NHANES III reference equations
Subjects willing and, in the opinion of the investigator, able to adjust current COPD therapy as required by the protocol

Exclusion Criteria

Significant diseases other than COPD, i.e. disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study
Current diagnosis of asthma or alpha-1 antitrypsin deficiency
Other active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary hypertension, or uncontrolled sleep apnea
Hospitalized due to poorly controlled COPD within 3 months prior to screening or during the Screening Period
Poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to screening or during the Screening Period
Lower respiratory tract infections that required antibiotics within 6 weeks prior to screening or during the Screening Period
Unstable ischemic heart disease, left ventricular failure, or documented myocardial infarction within 12 months of enrollment
Recent history of acute coronary syndrome, percutaneous coronary intervention, coronary artery bypass graft within the past three months
Congestive heart failure (CHF NYHA Class III/IV)
Clinically significant abnormal 12-lead ECG
Abnormal liver function tests defined as AST, ALT, or total bilirubin = 1.5 times upper limit of normal at Visit 1 and on repeat testing
Cancer not in complete remission for at least five years
History of hypersensitivity to ß2-agonists, glycopyrronium or other muscarinic anticholinergics, lactose/milk protein or any component of the MDI
Other protocol-defined inclusion/exclusioncriteria may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note